Table 1 Patient-level changes of PSA and PSMA PET metrics
Patient ID | miTNM at baseline | Type of ARSi | VISIT 1 Baseline | VISIT 2 1-week post ARSi | VISIT 3 3-months post ARSi | Follow-up 6-months | Follow-up 9-months | Follow-up 12-months | 1-year outcome | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Serum PSA Baseline | PSMA-VOL | SUVmean | SUVmax | Serum PSA 1-week | PSMA-VOL | SUVmean | SUVmax | Serum PSA 3-months | PSMA-VOL | SUVmean | SUVmax | Serum PSA (6-months) | Serum PSA (9-months) | Serum PSA (12-months) | ||||
ARSI-01 | mi T2 N0 M0 | Enzalutamide | 7.1 | 13.3 | 10.9 | 23.2 | 3.5 (− 51%) | 7.7 (− 42%) | 6.9 (− 37%) | 12.3 (− 47%) | 0.05 (− 99%) | 4.4 (− 67%) | 4.1 (− 62%) | 6.21 (− 73%) | < 0.02 | < 0.02 | < 0.02 | Favorable |
ARSI-02 | mi T0 N1 M1a M1b | Enzalutamide | 72.2 | 1019 | 5.4 | 16.6 | 60.3 (− 16%) | 1309(+ 38%) | 5.9 (+ 9%) | 22.7 (+ 37%) | 34 (− 53%) | 1160 (+ 14%) | 5.2 (− 4%) | 16.95 (+ 2%) | DECEASED | Unfavorable | ||
ARSI-03 | mi T0 N0 M1b | Abiraterone | 0.2 | 18.7 | 4.4 | 14.6 | 0.1 (50%) | 19.1 (+ 2) | 5.2 (+ 18%) | 17.5 (+ 20%) | 0.05 (− 75%) | 17.7 (− 5%) | 5 (+ 14%) | 13.57 (− 7%) | 0.54 | 0.38 | 0.64 | Unfavorable |
ARSI-04 | mi T2 N1 M1a M1b | Enzalutamide | 11.6 | 1385 | 6.8 | 58.5 | 9.5 (− 18%) | 1536 (+ 11%) | 7.3 (+ 7%) | 69.9 (+ 19%) | BCR before visit #3—but declined PET #3 | Unfavorable | ||||||
ARSI-05 | miT0 N0 M0 | Abiraterone | 0.33 | 0 | 0 | 0 | 0.19 (− 42%) | 0 | 0 | 0 | < 0.01 | 0 | 0 | 0 | < 0.01 | DECEASED due to non-PCa related death | Favorable | |
ARSI-06 | mi T0 N1 M1a | Apalutamide | 98.5 | 136 | 12 | 25.7 | 120 (+ 22%) | 140 (+ 3%) | 11.7 (− 3%) | 25.1 (− 2%) | 134 (+ 36%) | 127 (− 7%) | 10.09 (− 9%) | 28.17 (+ 10%) | 21.5 | 7.3 | 4.2 | Favorable |
ARSI-07 | mi T0 N1 M1a | Abiraterone | 2.9 | 23 | 11.4 | 42.7 | 3.1 (+ 7%) | 25(+ 9%) | 13.2 (16%) | 53.8 (+ 26) | 2 (− 31%) | 26 (+ 13%) | 11 (− 4%) | 53.35 (+ 25%) | 0.81 | n/a | 1.15 | Unfavorable |
ARSI-08 | mi T0 N0 M1b | Enzalutamide | 17 | 46 | 8.2 | 20.3 | 12.9 (− 24%) | 48 (+ 4%) | 8.4 (+ 2%) | 23.4 (+ 15%) | 25.5 (+ 50%) | BCR at 3 months, but declined PET #3 | Unfavorable | |||||
ARSI-09 | mi T0 N1 M1a M1b | Enzalutamide | 67.3 | 895 | 7.4 | 33.1 | 113 (+ 67%) | 1105 (+ 23%) | 8.1 (+ 9%) | 41.2 (+ 24%) | DECEASED | Unfavorable | ||||||